Skip to main content

Rossari Biotech debuts at Rs 670 with 58% premium over IPO price

The listing premium was much higher than the grey market premium (of around Rs 160-180 per share) as well as analysts' expectations of Rs 130-175 per share.

The Mumbai-based specialty chemical maker Rossari Biotech started the first trading day with a whopping 57.65 percent premium over its IPO price on July 23.

The stock opened at Rs 670 on the BSE, up by Rs 245 over the issue price of Rs 425 per share, while on the National Stock Exchange, it debuted at Rs 669.25, a 57.47 percent premium over IPO price.

It was much higher than the grey market premium (of around Rs 160-180 per share) as well as analysts' expectations of Rs 130-175 per share.

At 10:01 hours IST, the stock was trading at Rs 675 on the BSE, up by Rs 250 or 58.82 percent over issue price with a volume of 3.83 lakh shares.

The exchange has fixed a 20 percent upper and lower circuit limit at Rs 804 and Rs 536 respectively, over its opening price of Rs 670.

On the National Stock Exchange, the share price traded at Rs 676.75, up by Rs 251.75 or 59.24 percent over IPO price, with volumes of 40,88,564 equity shares.

The Rs 496-crore initial public offering of Rossari Biotech had seen a hefty subscription of 79.37 times during July 13-15.

The public issue consisted a fresh issue of Rs 50 crore and offer for sale of 1.05 crore shares by promoters Edward Menezes and Sunil Chari.

Promoters and promoter group's shareholding in the company reduced to 72.69 percent post issue, from 95.06 percent earlier.


The company will utilise fresh issue proceeds for repayment/prepayment of certain indebtedness (including accrued interest) and funding working capital requirements, while it will not receive any funds from offer for sale.

Rossari manufactures majority of its products in-house from its Silvassa manufacturing facility which has an installed capacity of 1,20,000 MTPA. Now the company is currently setting up another manufacturing facility at Dahej in Gujarat with a proposed installed capacity of 1,32,500 MTPA which will enjoy proximity to the deep water, multi-cargo port of Dahej. The proposed state-of-the-art facility will be fully operational by March 2021.

Manufacturing of disinfectants & sanitizers as part of the Home, Personal Care & Performance Chemicals led the company's products to get categorized under essential goods, thus its manufacturing facility at Silvassa was not shut down during COVID-19 lockdown period.

Previously, company's business was much dependent on the textile space (nearly 71 percent revenue came from textile in FY18 which reduced to 44 percent in FY20), but steadily company has brought down the revenue share and simultaneously the revenue share of Home & Personal care division has increased and current it accounts nearly 47 percent of FY20 revenue, which turns a big positive for Rossari Biotech, said Ashika Stock Broking.

Source - Moneycontrol

 


Comments

Popular posts from this blog

US investors' rights law firm announces probe against HDFC Bank

  The investigation is reportedly resulting from allegations that HDFC Bank may have issued materially misleading business information to the investing public.   American Law firm, Rosen Law, has announced an investigation of potential securities claims on behalf of shareholders of HDFC Bank. The firm is also preparing for a class action suit on behalf of bank’s shareholders. The investigation is reportedly resulting from allegations that HDFC Bank may have issued materially misleading business information to the investing public. Rosen Law, on its website, asked investors to provide their details if they have purchased HDFC Bank Limited securities and would like to receive information about the investigation concerning the class action to recover the investor losses in HDFC Bank Limited securities. “A representative of The Rosen Law Firm will contact you at no cost to you and provide you detailed information concerning the proposed class action to rec...

At 156.6 Times, Burger King IPO Receives The Second Largest Subscription In 2020

The state-owned defence company, Mazagon Dock Shipbuilders' Rs 443-crore IPO had seen the highest subscription in 2020 at 157.4 times The initial public offering of Burger King, one of the fastest growing quick service restaurant chains in India with 268 outlets, turned out to be the third issue in the calendar year 2020 to cross the subscription mark of 150 times. With a subscription of 156.6 times, it has received the second highest subscription in the current year after Mazagon Dock Shipbuilders. Burger King India targets to open 700 restaurants by December 2026. The Rs 810-crore IPO was subscribed 156.6 times overall during December 2-4 as it received bids for 1,166 crore equity shares against offer size of 7.44 crore equity shares (excluding anchor book portion). The strong interest in the issue was owing to attractive valuations, strong brand positioning, healthy financial prospects, expected robust store expansion plans of the quick service restaurant industry in I...

IT stocks rally, TCS hits new high; Wipro, Infosys, HCL Tech gain 2-4% each

Wipro added over 4 percent after the IT firm said its Board will consider a buyback plan on October 13. L&T Infotech, Infosys, HCL Tech, Mphasis, Tech Mahindra and Mindtree were the other gainers. The Indian stock market is trading higher for the sixth day in a row with Sensex jumping 479.35 points or 1.2 percent at 40358.30, and the Nifty gaining 132.20 points or 1.13 percent at 11871.10. The market rally was largely aided by IT stocks with the index jumping almost 4 percent led by index heavyweight Tata Consultancy Services (TCS) which hit new high. The company reported a profit after tax of Rs 7,475 crore for the quarter ended September 2020, registering a 6.7 percent sequential growth. The board members of the company have approved a proposal to buy back up to 5,33,33,333 equity shares of company, being 1.42 percent of the total paid up equity share capital, at around Rs 3,000 per equity share for an aggregate amount up to Rs 16,000 crore. Research and broking firm ICIC...